03613 TONGRENTANGCM
- 9.290
- +0.040+0.43%
TONGRENTANGCM News
Some mainland pharmaceutical stocks rose, with Sihuan Pharm (00460) up 3.85%. Institutions pointed out that drug price monitoring and governance are expected to help the industry's health.
Mainland pharmaceutical stocks have risen partially, with Sihuan Pharm (00460) up 3.85%, Haohai Biotech (06826) up 2.68%, Shanghai Pharma (02607) up 2.08%, Sinopharm (01099) up over 1%, TongrentangCM (03613) and Chinares Pharma (03320) following suit. Citic Sec pointed out that many places have launched drug price comparison platforms recently, but the bank believes that comparison does not mean price limitation. The Medical Insurance Bureau launched a special campaign of "going online stores, checking drug prices, comparing data, and cracking down on governance". The regulation of drug prices is not only about seeking low stock price, but also about eliminating price discrimination.
TONGRENTANGCM To Go Ex-Dividend On June 12th, 2024 With 0.33 HKD Dividend Per Share
June 7th - $TONGRENTANGCM(03613.HK)$ is trading ex-dividend on June 12th, 2024. Shareholders of record on June 13th, 2024 will receive 0.33 HKD dividend per share on June 24th, 2024. The ex-divide
Tong Ren Tang Chinese Medicine Appoints CEO
Tong Ren Tang Chinese Medicine (HKG:3613) has appointed Wang Chi as its new chief executive officer, effective May 10, according to a filing with Hong Kong Exchange last Friday. The acting CEO Chen Fe
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 24
According to the Zhitong Finance App, Tong Ren Tang Sinopharm (03613) announced that it will pay a final dividend of HK$0.33 per share for the year ended 31 December 2023 on June 24, 2024.
TONGRENTANGCM: Postponement and Rescheduling of Date of Annual General Meeting and Change of Book Closure Period
Tong Ren Tang Sinopharm (03613.HK) appoints Wang Chi as CEO
Gelonghui, May 10, 丨 Tong Ren Tang Sinopharm (03613.HK) announced that Mr. Wang Chi was appointed as the company's executive director, CEO and member of the Competition Executive Committee, effective May 10, 2024. The board of directors further announced that since Mr. Wang was appointed as the company's CEO, Mr. Chen Fei, executive director, acting CEO and executive deputy general manager of the company will no longer serve as acting CEO. Effective May 10, 2024, he will continue to serve as the company's executive director and executive deputy general manager.
Tong Ren Tang Chinese Medicine (03613): Issued a certificate of registration for proprietary Chinese medicines
According to Zhitong Finance App, Tong Ren Tang Sinopharm (03613) issued an announcement. The company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, which allows the sale of “Angelica Blood Supplementation Granules [Tong Ren Tang]” in Hong Kong.
Tong Ren Tang (600085.SH): “Angelica Blood Supplement Granules [Tong Ren Tang]” obtained the Hong Kong Proprietary Chinese Medicine Registration Certificate
Zhitong Finance App News, Tong Ren Tang (600085.SH) issued an announcement. Recently, Beijing Tongrentang Sinopharm Co., Ltd. (hereinafter referred to as Tongrentang Sinopharm), the company's holding company, received the “Certificate of Registration for Proprietary Chinese Medicine” issued by the Hong Kong Traditional Chinese Medicine Administration, permitting the sale of “Angelica Blood Supplement Granules [Tong Ren Tang]” in Hong Kong. According to the announcement, after receiving the registration certificate for proprietary Chinese medicines issued by the Hong Kong Traditional Chinese Medicine Administration, Tongrentang Sinopharm's angelica blood supplement granules “Tong Ren Tang” can be sold in Hong Kong, which will help enrich its product line and facilitate its market expansion. The one with the above registration certificate
同仁堂國藥：2023年年報
Gelonghui Fund Daily Report | 10 billion fund manager's big move!
Focus on the latest fund information
Tong Ren Tang Sinopharm (03613): Chen Fei appointed as acting CEO
Tong Ren Tang Sinopharm (03613) announced that Yu Jin has resigned as the company's executive director and CEO due to personal matters...
Damo: Maintaining Tong Ren Tang Sinopharm's (03613) “Gain” Rating and Lowering the Target Price to HK$15
According to the optimistic hypothesis, Tongrentang Sinopharm (03613) sales growth is 20% or more per year.
Tong Ren Tang Sinopharm Announces 2023 Annual Results Profit attributable to shareholders of HK$540 million, a decrease of 16.3% year-on-year
Tong Ren Tang Sinopharm (03613) announced its results for the year ended December 31, 2023. The group achieved revenue of HK$1,525 million, a year-on-year decrease of 11.9%; profit attributable to company owners of HK$540 million, a year-on-year decrease of 16.3%; basic profit per share of HK$0.65; and proposed to pay a final dividend of HK$0.33 per common share.
Tong Ren Tang Sinopharm will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of HK$0.33 per share on June 17, 2024.
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of 0 per share on June 17, 2024...
Tong Ren Tang Sinopharm (03613) announced 2023 annual results. Profit attributable to shareholders of HK$540 million decreased by 16.3% year-on-year
Tongrentang Sinopharm (03613) announced its annual results for the year ended December 31, 2023, and the group achieved acceptance during the period...
TONGRENTANGCM: (1) Annual Results Announcement For the Year Ended 31 December 2023; and (2) Inside Information - Revised Dividend Policy
Tong Ren Tang Sinopharm (03613.HK) will hold a board meeting on March 14 to approve the annual results
Gelonghui, March 4, 丨 Tong Ren Tang Sinopharm (03613.HK) announced that the company's board of directors meeting will be held on March 14, 2024 (Thursday) to approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider paying a final dividend (if any).
TONGRENTANGCM: Date of Board Meeting
Tong Ren Tang Sinopharm (03613) fell 4.90% and now reports 8.750 yuan, a 52-week low
As of 16:08, Tongrentang Sinopharm (03613) is down 4.90% from yesterday's closing price and now reports a 52-week low of $8.750; the trading volume is 5.202,900 shares, with a turnover of HK$46.48,800.
Analysis
Price Target
No Data
